Seltorexant is an investigational drug.
There have been 18 clinical trials for Seltorexant.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 15th 2020.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Janssen Research & Development, LLC, Minerva Neurosciences, and [disabled in preview].
There are four US patents protecting this investigational drug and one hundred international patents.